Treatment of Sjögren Syndrome in a Mother of Reproductive Age with Anti-Ro/La Antibodies and Fetal Incomplete Congenital Heart Block

This protocol addresses a specific, high-stakes presentation: a woman of reproductive age diagnosed with Sjögren syndrome who tests positive for anti-Ro/La antibodies, with fetal or neonatal incomplete congenital heart block identified.

Clinical Scenario

Anti-Ro/La antibody positivity in Sjögren syndrome carries direct fetal risk. Ro-associated congenital heart block — a complication not captured in standard Sjögren disease activity scoring — is recognised for its prognostic significance and requires specific management consideration during the reproductive period.

Treatment Approach — Partial Overview

The structured first-line regimen for this scenario combines a fluorinated corticosteroid with an antimalarial agent. The full protocol — including the specific agents, their use in combination, and all clinical decision points — is available via the link below.

Complete regimen details, monitoring parameters, and the full evidence base remain behind the access link.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/annrheumdis-2019-216114

Ro-associated congenital heart block (not included in the ESSDAI) was also included due to its prognostic significance.

HCQ: hydroxychloroquine 200 mg/day.

View source ↗